A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

TORONTO, ON / ACCESS Newswire / / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and ...

TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

There are few treatment options for patients who develop BCG-unresponsive bladder cancer, which raises the risk of the cancer spreading throughout the body. Around 40% of patients don’t respond ...

Generate complete treatment schedules based on TURBT date Visual timeline ... T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...